FGEN Profile
FibroGen, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics aimed at addressing serious unmet medical needs. The company’s flagship product, Roxadustat, is an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylases. Roxadustat has advanced through Phase III clinical development for the treatment of anemia associated with chronic kidney disease in the United States, Europe, China, and Japan. Additionally, it is undergoing Phase II/III trials in China for treating anemia related to myelodysplastic syndromes, reflecting FibroGen's commitment to addressing a wide range of anemia-related conditions.
Another key product in FibroGen’s pipeline is Pamrevlumab, a human monoclonal antibody designed to inhibit the activity of connective tissue growth factor. This therapeutic candidate is in Phase III clinical trials for multiple indications, including idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease. Pamrevlumab is also undergoing Phase III trials for Duchenne muscular dystrophy, highlighting the company’s broad therapeutic focus and dedication to treating complex fibrotic and degenerative diseases.
FibroGen has established strategic collaboration agreements with major pharmaceutical companies, including Astellas Pharma Inc. and AstraZeneca AB. These partnerships are crucial in advancing the development and commercialization of FibroGen’s therapeutics, leveraging the expertise and resources of leading industry players to accelerate the delivery of innovative treatments to patients.
Incorporated in 1993 and headquartered in San Francisco, California, FibroGen has built a robust pipeline and research infrastructure over the years. The company's focus on unmet medical needs, combined with its strategic collaborations, positions it as a key player in the biopharmaceutical sector, committed to advancing the science of treating complex diseases and improving patient outcomes.
|
